IPP Bureau

USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility
USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility

By IPP Bureau - October 31, 2022

The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue

Zydus receives final approval from USFDA for Acetaminophen injection
Zydus receives final approval from USFDA for Acetaminophen injection

By IPP Bureau - October 30, 2022

Acetaminophen injection had annual sales of US $72 million in the United States according to IQVIA data

Kopran acquire assets of Abhinandan Rasayan
Kopran acquire assets of Abhinandan Rasayan

By IPP Bureau - October 30, 2022

Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity

USFDA issues Form 483 for Parawada unit of Laurus Labs
USFDA issues Form 483 for Parawada unit of Laurus Labs

By IPP Bureau - October 30, 2022

The observation is procedural in nature and the company will address the observation within stipulated timelines.

Madhur Gundecha appointed CFO of Astec Lifesciences
Madhur Gundecha appointed CFO of Astec Lifesciences

By IPP Bureau - October 30, 2022

He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.

21.4 lakh TB cases notified in India in 2021
21.4 lakh TB cases notified in India in 2021

By IPP Bureau - October 30, 2022

Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today

Recent launch of 5G will bring a new revolution in digital healthcare: Dr. Singh
Recent launch of 5G will bring a new revolution in digital healthcare: Dr. Singh

By IPP Bureau - October 30, 2022

India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

By IPP Bureau - October 30, 2022

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track

Mandaviya addresses Second G20 Health Ministers Meet
Mandaviya addresses Second G20 Health Ministers Meet

By IPP Bureau - October 28, 2022

He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods

Centre deploys high-level team to Kerala to investigate Avian Influenza Outbreak
Centre deploys high-level team to Kerala to investigate Avian Influenza Outbreak

By IPP Bureau - October 28, 2022

The team will also assist the state health departments in terms of public health measures, management guidelines and protocols to manage the increasing cases of Avian Influenza

Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23
Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23

By IPP Bureau - October 28, 2022

The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit
ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit

By IPP Bureau - October 28, 2022

It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

By IPP Bureau - October 28, 2022

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

By IPP Bureau - October 27, 2022

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr

Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr

By IPP Bureau - October 27, 2022

The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022

Latest Stories

Interviews

Packaging